LGALS3 and cancer: Therefore, the high selectivity of GB1211 and therapeutic effect observed by Zetterberg et al. [27], along with the safety and PK findings reported here, suggest GB1211 may be an advantageous treatment option for fibrotic disease, cancer and other galectin-3-mediated conditions.